Perospirone

Perospirone
Clinical data
Trade names	Lullan
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	92%
Metabolism	Hepatic
Elimination half-life	1.9–2.5 hours
Excretion	Renal (0.4% as unchanged drug)
Identifiers
	IUPAC name (3aS,7aR)-2-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione;
CAS Number	150915-41-6 ;
PubChem CID	115368;
IUPHAR/BPS	7556;
ChemSpider	16737064 ;
UNII	N303OK87DT;
CompTox Dashboard (EPA)	DTXSID2048163 ;
Chemical and physical data
Formula	C23H30N4O2S
Molar mass	426.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C4N(CCCCN1CCN(CC1)C\3=N\SCc2ccccc2/3)C(=O)[C@@H]5CCCC[C@H]45;
	InChI InChI=1S/C24H32N4O2S/c29-23-20-9-3-4-10-21(20)24(30)28(23)12-6-5-11-26-13-15-27(16-14-26)22-19-8-2-1-7-18(19)17-31-25-22/h1-2,7-8,20-21H,3-6,9-17H2/t20-,21+ ; Key:GTAIPSDXDDTGBZ-OYRHEFFESA-N ;
	(what is this?) (verify)

Perospirone (Lullan) is an atypical antipsychotic of the azapirone family. It was introduced in Japan by Dainippon Sumitomo Pharma in 2001 for the treatment of schizophrenia and acute cases of bipolar mania.